Predict drug-drug interactions and the safety margin
The translation of research findings to humans is one of the greatest challenges. Improve patient safety and assess the benefit-risk ratio with PharmaPendium's calculation tools for predictive analysis: - Drug-Drug Interaction Risk Calculator (DDIRC) - Safety Margin Tool
Purposeful prediction, powerful translation.
Predict drug-drug interactions with confidence
The Drug-Drug Interaction Risk Calculator (DDIRC) was developed in collaboration with Sanofi, Merck, Servier, Boerhinger Ingelheim and others with the aim of improving patient safety. The tool is part of PharmaPendium's DMPK (Drug Metabolism and Pharmacokinetics) solution.
The DDIRC helps you predict harmful drug-drug interactions (DDI) fast and as early as possible in drug development. Calculate the area under the curve (AUC) changes to optimize clinical trial design and avoid unnecessary DDI trials. An entire arm of a clinical study and time may be saved. The DDIRC supports your decision making to fail weak candidates fast and select the most promising.
This mechanistic static tool includes perpetrators and victims along with their in vitro and in vivo data — the most comprehensive dataset in a single solution. The DDIRC is compliant with the 2020 FDA guidelines, as well as with EMA and PMDA.
Sanofi/DNDi use PharmaPendium's Drug-Drug Interaction Risk Calculator in successful EMA and FDA submissionsLearn how DDIRC predictions supported the authorization of fexinidazole. (opens in new tab/window)
Predict off-target adverse drug reactions
PharmaPendium’s new Safety Margin Tool supports you in terms of secondary pharmacology. It can help you predict the risk of off-target adverse drug reactions (ADRs) for your drug candidates, answering questions such as:
What dose of a small molecule is likely to be safe for use in humans?
Which drug candidate is likely to be the safest?
The Safety Margin Tool was developed in a longstanding collaboration with Novartis in response to biopharma organizations’ needs.
By combining target affinity data from literature and PK/PD data from marketed and withdrawn drugs, a safety margin is calculated. This tool will help you predict which drug candidates need be failed as early as possible because of high probability of off-target ADRs and which ones will likely become successful additions to your drug portfolio.